If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
336
results.
Updated on
20/08/2026 [07:44:00]
Results 25 to 50 of 336
Absstract of: CN122337553A
The invention discloses a diagnosis and treatment path recommendation method based on IBS multi-dimensional data, and relates to the technical field of intelligent diagnosis and treatment, and the method comprises the following steps: S1, constructing an IBS treatment scheme library which comprises standardized treatment schemes corresponding to different diagnosis types and different disease severity degrees of IBS, the standardized treatment schemes at least comprise review suggestions, drug recommendation, probiotic recommendation and nursing guidance, and each treatment scheme is associated with a corresponding IBS multi-dimensional data feature threshold. According to the diagnosis and treatment path recommendation method based on the IBS multi-dimensional data, the limitation of single diagnosis data dimension in the prior art is broken through, four core dimensions of symptom data, physical sign data, laboratory examination data and medical history data of a patient are comprehensively integrated, and the symptom data is ensured to be free of omission by combining dual modes of patient autonomous filling and reporting and doctor inquiry; objectivity of physical sign data is guaranteed through professional medical equipment, laboratory inspection data are synchronously obtained from a hospital inspection system, and errors are reduced.
Absstract of: CN122326775A
The invention relates to a method for analyzing a relationship between intestinal microbiota and an emotional symptom of an IBS patient. The method comprises the following steps: determining a causal relationship between the intestinal microbiota and the emotional symptom of the IBS patient; determining that the emotional symptom is caused by reduction of abundance of A. shahii in the intestinal microbiota; determining that the emotional symptom is caused by the reduction of indole produced by metabolism of the intestinal microbiota, and the reduction of indole is caused by the reduction of abundance of A. shahii; determining that the emotional symptom is caused by the decrease of TnAse generated by the intestinal microbiota, the decrease of TnAse is caused by the decrease of abundance of A. shahii, and the decrease of indole is caused by the decrease of TnAse; determining that the emotional symptom is caused by the weakening of AhR signal transduction in the vDG of the IBS patient, and the weakening of AhR signal transduction is caused by the reduction of indole; and determining that the emotional symptoms are caused by the weakening of vDG granular cell viability and the weakening of the vDG granular cell viability is caused by the weakening of AhR signal transduction, thereby obtaining an analysis result that the intestinal microbiota regulates and controls the emotional symptoms through the A. shahii-TnAse-indole-AhR-vDG signal pathway.
Absstract of: CN122337628A
The invention belongs to the technical field of medical diagnosis assistance, and provides an inflammatory bowel disease assessment method and system.The method includes the steps that biological sample data of a target object is obtained and preprocessed to standardize index data, and the index data is obtained; and calculating multiple scores representing the individual state of the target object based on the preprocessed biological sample data, and constructing a comprehensive evaluation index for quantitatively evaluating the inflammatory bowel disease of the target object based on the scores. According to the scheme provided by the invention, a multi-dimensional comprehensive evaluation index is constructed by integrating multiple index data, so that the pathophysiological essence of the inflammatory bowel disease can be comprehensively and accurately reflected, misdiagnosis or missed diagnosis caused by single-dimensional evaluation is effectively avoided, and the diagnosis accuracy is improved. And a non-invasive, convenient and standardized technical solution is provided for diagnosis, illness monitoring and curative effect evaluation of the inflammatory bowel disease.
Absstract of: US20260185998A1
Methods of diagnosing Crohn's disease and ulcerative colitis in subjects is provided based on the determination of metabolites in urine samples, such as serine, hypoxanthine, kynurenine, threonine, indoxylsulfate, phenylacetylglutamine, 5-hydroxy-6-indolyl-O-sulfate, 5-(δ-carboxybutyl) homocysteine, sialic acid, guanidinosuccinic acid (GSA), glutamyl(iso) leucine, trigonelline, cresol sulfate, an anion having m/z: RMT: polarity of 345.1553:0.770: n, aminohippurate: GSA ratiometric biomarker, unknown anion (160.0615:0.830: n): tyrosine ratiometric biomarker and GSA×Tyr: AHA×(an anion having m/z: RMT: polarity of 160.0615:0.830: n) ratiometric biomarker.
Absstract of: CN122297639A
The invention provides an application of NUCB1 in preventing and/or treating autoimmune diseases, and particularly provides an application of an NUCB1 gene, or a protein thereof or an accelerant thereof in preparing a composition or a preparation, and the composition or the preparation is used for preventing and/or treating the autoimmune diseases. The NUCB1 gene, or the protein thereof, or the promoter thereof can significantly prevent and/or treat autoimmune diseases, especially can effectively treat systemic lupus erythematosus, atopic dermatitis, rheumatoid arthritis, psoriasis, multiple sclerosis or Crohn's disease.
Absstract of: CN122278770A
The invention relates to a method for screening drugs for diseases closely related to unmarked G-protein coupled receptors (GPCR), in particular to an unmarked cell screening model of a GPR183 receptor and application of the unmarked cell screening model in preparation of drugs. And the unmarked cell screening model is a stably transfected cell strain CHO-K1-GPR183 with high expression of a GPR183 receptor. The GPR183 receptor stimulant compound N-demethylated nuciferine is obtained by screening through the GPR183 cell screening model established in the invention. At present, researches show that the GPR183 receptor is closely related to the occurrence and development of neuroinflammation/autoimmune diseases such as multiple sclerosis, colitis, type I diabetes and arthritis, cancers and metabolic diseases, so that a seedling compound can be provided for the development of medicines for related diseases.
Absstract of: WO2026136763A1
Provided are methods of generating a polygenic score (PGS) to identify or predict interleukin- 18 (IL- 18) driven disease in a subject, along with methods of treating subjects with various diseases and conditions, such as inflammatory bowel disease, determined to have IL- 18 driven disease or inflammasome-mediated disease based on a PGS.
Absstract of: WO2025038942A1
Disclosed are methods for imaging inflammation associated with inflammatory bowel disease (IBD), including administering to a subject a prostate-specific membrane antigen (PSMA)-targeted imaging agent and taking an image.
Absstract of: CN122259877A
The invention discloses application of TLR8 in preparation of a product for diagnosing and treating ulcerative colitis, and belongs to the technical field of biological medicines. The invention provides an application of TLR8 in preparation of an ulcerative colitis diagnostic product, the diagnostic product is used for detecting the expression level of TLR8 in a peripheral blood sample, and the diagnostic product comprises a detection reagent, a detection kit and a detection chip; meanwhile, the invention provides application of TLR8 in preparation and/or screening of drugs for treating ulcerative colitis and application of a TLR8 inhibitor in preparation of drugs for treating or relieving ulcerative colitis. The medicine can be used for reducing the phosphorylation level of p65 in an NF-kappa B pathway by inhibiting the expression of TLR8, so that the intestinal inflammatory response is relieved. The invention clarifies the association between TLR8 and ulcerative colitis, provides a new target and detection means for the early diagnosis of ulcerative colitis, provides a new idea and drug research and development direction for the treatment of the disease, and has important clinical application value and industrialization prospect.
Absstract of: CN122245701A
The invention provides an inflammatory bowel disease subtype diagnosis model and a construction method thereof, and the diagnosis model is characterized in that an RNA editing characteristic spectrum capable of specifically distinguishing Crohn's disease and ulcerative colitis is extracted from a PBMC sample obtained by minimally invasive acquisition through a set of innovative bioinformatics flow, and the RNA editing characteristic spectrum is used for constructing the inflammatory bowel disease subtype diagnosis model. And a machine learning model is constructed and trained by using the characteristic spectrum, and finally accurate and automatic diagnosis of the IBD subtype is realized.
Absstract of: CN122229982A
The invention belongs to the technical field of marine product function application, functional food and biology, and discloses oyster oligopeptide for relieving dextran sodium sulfate (DSS) induced ulcerative colitis and a preparation method and application thereof. A DSS induced human normal colonic epithelial cell injury model is taken as a guide, oyster meat is subjected to enzymolysis, degreasing and alcohol precipitation preparation and purification to obtain oyster zymolyte, two oyster peptides are obtained through identification, bioinformatics screening and synthesis verification, and the amino acid sequences are shown as SEQ ID NO.1-2. The oyster oligopeptide has relatively strong antioxidant and anti-inflammatory activity, can effectively relieve DSS-induced NCM460 cell injury, has an effect superior to that of a positive control 5-aminosalicylic acid, and can be used for preparing medicines for relieving ulcerative colitis and foods and health-care products for adjuvant therapy of ulcerative colitis.
Absstract of: WO2026128869A1
Personalized methods of determining a reference PDE4 Inhibitor Resistance Metric for treating a future patient in need of treatment, and methods of treating a subject with an inflammatory bowel disease are provided.
Absstract of: CN122218255A
The invention discloses a combined marker for detecting Crohn's disease and application of the combined marker, and relates to the technical field of biology and medicine. The combined marker is prepared from the following components: chenodeoxycholic acid, lithocholic acid, ursodeoxycholic acid, glycochenodeoxycholic acid, glycolithocholic acid, glycoursodeoxycholic acid, taurochenodeoxycholic acid, taurocholic acid, taurocholic acid, tauroursodeoxycholic acid, cholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid and taurodeoxycholic acid. Adding glycylcholic acid sulfate and isolithocholic acid; the combined marker can be used for clinical diagnosis or monitoring of Crohn's disease. The metabonomics combined marker for Crohn disease diagnosis is explored, a diagnosis and identification method which is simple and convenient to detect, low in cost and easy to accept by patients is created, a traditional diagnosis mode can be well replaced, and the metabonomics combined marker has great significance in clinical diagnosis and treatment of Crohn diseases and has popularization value.
Absstract of: AU2024402123A1
Aspects of the disclosure provides composition and methods for treating a subject having inflammatory bowel disease, the method comprising administering to the subject a hemojuvelin (HIV) antagonist (e.g., anti-HJV antibody).
Absstract of: US20260159887A1
0000 Inflammatory bowel disease (IBD) in humans and dogs and other companion animals is characterized by infiltration of lymphocytes and macrophages into the mucosa and submucosa and clinical signs of gastrointestinal (GI) dysfunction (diarrhea, malabsorption, weight loss). Alteration of the gut environment and development of dysbiosis may allow the overgrowth of pathogenic bacteria and induction of intestinal injury and inflammation in IBD. What is needed are novel methods that allow for rapid diagnosis of IBD (and follow-up monitoring) and treatment of the disease. The present disclosure relates to methods for diagnosing and treating inflammatory bowel disease (IBD) or gastrointestinal lymphoma.
Absstract of: CN122145556A
The invention discloses a granzyme B targeting complex, a radiopharmaceutical and an imaging application of the granzyme B targeting complex in intestinal immune abnormal activity, and belongs to the field of nuclear medicine diagnosis and treatment. The complex is subjected to covalent modification, the recognition peptide and granzyme B are subjected to specific non-covalent binding firstly, then irreversible covalent linkage is triggered by means of the proximity effect, and the technical bottlenecks that an existing granzyme B probe is low in target tissue intake, short in-vivo residence time and narrow in imaging window are effectively solved. The selective retention capacity and the imaging specificity of the probe at a target part are obviously improved. The complex and the radiopharmaceutical disclosed by the invention can specifically target granzyme B released by abnormal immune activity of an intestinal diseased region, realize intestinal inflammations such as Crohn's disease and ulcerative colitis and noninvasive, dynamic and quantitative nuclear medicine imaging of aGVHD, can accurately evaluate the abnormal immune activity of the intestinal tract and monitor the treatment effect, and have good application prospects. A core tool is provided for early diagnosis and precise diagnosis and treatment of the diseases, and the kit has important clinical transformation value and application prospect.
Absstract of: CN122150473A
The invention relates to the technical field of quality standard detection of traditional Chinese medicine preparations, in particular to a quality detection method of food retention removing and bowel relaxing capsules. According to the method for determining the characteristic chromatogram of the capsule for removing food retention and relaxing bowels, high performance liquid chromatography is adopted for determination, octadecylsilane chemically bonded silica is used as a filler, the column length is 250 mm, the inner diameter is 4.6 mm, and the particle size is 5 mu m. Acetonitrile is used as a mobile phase A, and a 0.2% phosphoric acid solution is used as a mobile phase B for elution; the flow rate is 1.0 ml per minute; the column temperature is 40 DEG C; and the detection wavelength is 265 nm. The method has the advantages of good specificity, good sample injection precision, good repeatability and good intermediate precision, and a test solution is stable at room temperature within 48 hours.
Absstract of: CN122140776A
The invention relates to a composition for preventing or treating inflammatory bowel diseases and application thereof, belongs to the technical field of inflammatory bowel diseases, and solves the problems that in the prior art, pathogenesis of intestinal symbiotic fungi mediated inflammatory bowel diseases is unclearly explained, and a treatment means for targeting fungi related signal channels is lacked. An inflammatory bowel disease intervention scheme based on flora interaction does not exist; existing therapeutic drugs are difficult to regulate and control the immune homeostasis of intestinal tracts, amplify regulatory T cells and the like. The invention provides a composition for preventing or treating inflammatory bowel disease and application thereof, the composition comprises at least one of a Dectin-2/CARD9 antagonistic antibody or small molecule inhibitor, an antifungal agent, a lactobacillus johnsonii WXY strain and/or L-glutamic acid, and the preservation number is CGMCC No.37794. According to the present invention, the colitis can be exacerbated through the Dectin-2-CARD9 pathway, the proliferation of the regulatory T cells mediated by Lactobacillus johnsonii and L-glutamic acid can be inhibited, the change of the marker composition in the inflammatory bowel disease patients can be verified, and the diagnostic marker and the potential treatment target can be provided for the inflammatory bowel disease.
Absstract of: CN122158089A
The invention discloses an out-of-hospital grading diagnosis method based on IBS disease, and relates to the technical field of medical diagnosis, and the method comprises the following steps: S1, obtaining multi-dimensional information related to IBS disease provided by a patient in an out-of-hospital scene; s2, performing standardized preprocessing on the out-of-hospital multi-dimensional information to obtain feature data which can be input into an algorithm model; and S3, inputting the standardized feature data into a preset IBS grading diagnosis algorithm model, and outputting an IBS disease grading diagnosis result of the patient. According to the out-of-hospital grading diagnosis method based on the IBS disease, multi-dimensional out-of-hospital information is integrated, standardized preprocessing is combined to eliminate data errors, multi-feature screening and model optimization are adopted, a Roman IV diagnosis standard is referred to to train a model, meanwhile, diagnosis reliability is judged through confidence, and the misdiagnosis rate and the missed diagnosis rate are reduced; and a model iteration updating mechanism can continuously improve the diagnosis precision and adapt to the change of clinical requirements.
Absstract of: US20260152808A1
The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, a treatment comprising administration of an immune checkpoint inhibitor (ICI). The TOPOSCORE represents a robust biomarker predicting immunosensitivity and immunoresistance to ICI on an individual basis.
Absstract of: WO2026115199A1
The present invention is related to a method for determining or confirming inflammatory bowel disease (IBD) in a subject, the method comprising detecting the amount of keratin 18 (K18) and/or keratin 19 (K19) mRNA or protein in a biological sample obtained from said subject. The present method can also be used for differentiating microscopic colitis from IBD.
Absstract of: WO2026115801A1
Provided is an inflammatory bowel disease testing method. This inflammatory bowel disease testing method comprises (1) a step for detecting biomarkers in a biological sample collected from a subject. The biomarkers include: proHp and LRG; or proHp and CRP.
Absstract of: US20260153518A1
0000 A method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12, in a subject, a diagnostic drug containing a substance that specifically interacts with MMP12, and a therapeutic agent containing an MMP12 inhibitory substance.
Absstract of: CN122135993A
The invention relates to the technical field of ulcerative colitis prediction, in particular to an ulcerative colitis prediction model, a construction method and a prediction kit. The risk score of each sample is equal to 68.798 to 11.031 * relative expression quantity of HMGCS2, 46.586 * relative expression quantity of GCNT2, 20.391 * relative expression quantity of B4GALNT2, 5.719 * relative expression quantity of NAT8B, 26.562 * relative expression quantity of LPCAT1, 17.042 * relative expression quantity of PPARGC1A, 10.500 * relative expression quantity of ACSS2, 3.110 * relative expression quantity of PDK2, and 77.421 * relative expression quantity of HADHA. A risk score less than zero is defined as non-ulcerative colitis, and a risk score greater than zero is defined as ulcerative colitis. The invention provides the ulcerative colitis diagnosis model, the model can be suitable for rapid diagnosis of clinical samples, an objective and quantitative judgment basis is provided for UC diagnosis, and the problem that a traditional diagnosis method is insufficient in sensitivity and specificity is solved.
Nº publicación: CN122104886A 29/05/2026
Applicant:
浙江大学医学院附属邵逸夫医院（浙江省邵逸夫医院）
Absstract of: CN118581207A
The invention provides a marker for diagnosing systemic inflammation and application, the marker comprises ADGRE3mRNA or ADGRE3 protein, or ADGRE3mRNA fragment and ADGRE3 protein fragment, the marker content in samples of systemic inflammation patients and healthy people has significant difference, clinical verification shows that the marker is high in diagnosis sensitivity and specificity, and the marker can be applied to diagnosis of systemic inflammation. Therefore, systemic inflammation can be accurately diagnosed by detecting the transcription level of ADGRE3 mRNA or the expression level of ADGRE3 protein in an individual sample. Compared with an existing inflammation marker, the ADGRE3 mRNA and the ADGRE3 protein have higher sensitivity and specificity in the aspect of diagnosis of systemic inflammation.
BOPI
Electronic site
